CeriBell, Inc. (CBLL)
| Market Cap | 700.04M +17.7% |
| Revenue (ttm) | 95.07M +32.9% |
| Net Income | -60.37M |
| EPS | -1.63 |
| Shares Out | 37.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 179,573 |
| Open | 18.81 |
| Previous Close | 18.67 |
| Day's Range | 18.42 - 18.99 |
| 52-Week Range | 10.85 - 24.33 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.86 (+45.58%) |
| Earnings Date | May 11, 2026 |
About CBLL
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote acc... [Read more]
Financial Performance
In 2025, CeriBell's revenue was $89.06 million, an increase of 36.09% compared to the previous year's $65.44 million. Losses were -$53.41 million, 32.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CBLL stock is "Strong Buy." The 12-month stock price target is $26.86, which is an increase of 45.58% from the latest price.
News
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serio...
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlin...
CeriBell Transcript: Bank of America Global Healthcare Conference 2026
Record Q1 revenue and account growth were driven by sales force maturation, new strategies targeting regional hospital systems, and strong product adoption. New indications in neonate and delirium are progressing well, with positive early feedback and ongoing clinical research. Gross margin improved to 87% due to cost management and supply chain diversification.
Ceribell price target lowered to $25 from $28 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on Ceribell (CBLL) to $25 from $28 and keeps a Buy rating on the shares. The firm said Ceribell posted another…
CeriBell Q1 Earnings Call Highlights
CeriBell NASDAQ: CBLL reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company's strongest quart...
Ceribell reports Q1 EPS (52c), consensus (39c)
Reports Q1 revenue $26.5M, consensus $26.09M. “Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure monitoring pla...
Ceribell sees FY26 revenue $112M-$116M, consensus $113.18M
16:09 EDT Ceribell (CBLL) sees FY26 revenue $112M-$116M, consensus $113.18M
CeriBell Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 29% year-over-year to $26.5M, driven by record utilization and strong account additions. Gross margin remained high at 87%, and full-year guidance was raised to $112–$116M. Neonate/pediatric launches and delirium pilot mark key milestones.
CeriBell Earnings release: Q1 2026
CeriBell released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
CeriBell Quarterly report: Q1 2026
CeriBell has published its Q1 2026 quarterly earnings report on May 11, 2026.
Ceribell Reports First Quarter 2026 Financial Results
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serio...
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ser...
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ser...
CeriBell Proxy statement: Proxy filing
CeriBell filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
CeriBell Proxy statement: Proxy filing
CeriBell filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Ceribell receives 510(k) premarket notification for brain monitor headband
The FDA posted a 510(k) premarket notification notice for the Ceribell (CBLL) Brain Monitor Headband with a decision date of April 3. The FDA decision was “substantially equivalent,” according to…
CeriBell Slides: Corporate presentation
CeriBell has posted slides in relation to its latest quarterly earnings report, which was published on March 5, 2026.
CeriBell Transcript: TD Cowen 46th Annual Health Care Conference
Consistent outperformance and strong 2026 growth guidance are supported by expanded sales force and new product launches in neonatal, pediatric, and delirium indications. Operational efficiencies maintain high margins, while unique FDA clearances and AI capabilities differentiate from competitors.
CeriBell Transcript: 47th Annual Raymond James Institutional Investor Conference
A novel rapid EEG platform with AI-driven seizure detection achieved $89M in 2025 revenue and 36% growth, expanding its market with pediatric, neonate, and delirium indications. With only 3% U.S. market penetration, the company is focused on deeper hospital adoption, new indications, and leveraging its platform for future growth.
Ceribell price target lowered to $28 from $30 at Canaccord
Canaccord lowered the firm’s price target on Ceribell (CBLL) to $28 from $30 and keeps a Buy rating on the shares. The firm said they reported a solid beat for…
Ceribell reports Q4 EPS (36c), consensus (41c)
Reports Q4 revenue $24.78M, consensus $23.95M. “2025 was a milestone year for Ceribell (CBLL),” said co-founder and CEO Jane Chao. “We accelerated adoption across new and existing accounts, broadened ...
Ceribell sees FY26 revenue $111M-$115M, consensus $112.67M
The company said, “Ceribell (CBLL) expects revenue for the full year 2026 to be in the range of $111 million to $115 million, representing growth of approximately 25% to 29%…
CeriBell Earnings Call Transcript: Q4 2025
Delivered 36% revenue growth in 2025, expanded TAM to $3.5B, and achieved key FDA clearances for new indications. 2026 guidance calls for 25–29% revenue growth, with new product launches and deeper account penetration expected to drive upside.
CeriBell Annual report: Q4 2025
CeriBell has published its Q4 2025 annual report on February 24, 2026.
CeriBell Earnings release: Q4 2025
CeriBell released its Q4 2025 earnings on February 24, 2026, summarizing the period's financial results.